Skip to main content
Drug Discovery and Development

Small Molecules

Drug Discovery and Development

From drug discovery and development to quality control, let Agilent help your lab become more efficient

As the cost of bringing new drugs to market continues to grow so does the pressure to increase efficiency and productivity throughout the development cycle.

Speed to decision is critical.  You need to rapidly evaluate potential candidate compounds and confidently assess their effectiveness as therapeutic drugs. Agilent can help meet your needs in drug discovery with high throughput automated systems for compound identification in early discovery and with sophisticated, highly sensitive analytical systems that can provide quick answers to routine questions—for both expert users and trained technicians.

Developing small molecule pharmaceuticals requires efficient processes together with an evaluation of safety and efficacy. You have to make critical decisions from a variety of compound assessments - and  you need to be absolutely confident that you’re making the right choice.  Agilent solutions for ADME/PK, purification, impurities analysis, method development, and quality by design (QbD) provide the answers and efficiency you need with the reliability you expect from Agilent.

We understand that, in manufacturing and quality control, productivity and compliance are critical, and we have solutions to help you:
  • Identify incoming raw materials
  • Monitor volatile, semi-volatile, or non-volatile impurities
  • Evaluate dissolution properties
  • Determine content uniformity
Agilent understands your needs in pharmaceutical discovery, development, manufacturing, and quality control and has sample-to-data solutions that work together seamlessly. Let us help you rapidly move new pharmaceutical candidates toward approval and to patients

Follow Agilent’s Pharma LinkedIn Showcase:
Follow us on LinkedIn for continuous up to date Pharma news, events, publications

Refine By

Solution Areas

Featured Application Notes

Differential Analysis in Screening Assays for Extractable and Leachable Compounds

Agilent 6120B Single Quadrupole Walk-up for Multiuser Labs

Through-Container ID Verification of Polysorbates 20, 40, 60, and 80 with RapID

Featured Literature

Quality-by-Design Approach to Stability Indicating Method Development for Linagliptin Drug Product

A quality-by-design (QbD) approach to method development can potentially lead

Agilent 6470 QQQ LC/MS Robustness for Pharmaceuticals in Plasma Matrices

This appnote demonstrates the advantages of using an Agilent 6470 QQQ coupled with an Agilent RapidFire 365 High-throughput MS System.

Sensitive determination of impurities in achiral pharmaceuticals by supercritical fluid chromatography using the Agilent 1260 Infinity Analytical SFC System

Application note for the sensitive determination of impurities in achiral pharmaceuticals by supercritical fluid chromatography